期刊文献+

中药干预表皮生长因子受体抑制剂相关皮疹的荟萃分析 被引量:14

Effects of traditional Chinese medicine on epidermal growth factor receptor inhibitors induced rash:a meta-analysis
下载PDF
导出
摘要 目的:探索中药干预表皮生长因子受体抑制剂(EGFRIs)相关皮疹的疗效及安全性。方法:检索Pubmed、Cochrane对照试验、中国学术期刊数据库、中国知网数据库中关于中药干预EGFRIs相关皮疹的随机对照试验,并手工检索补充相应文献。采用Revman软件对符合标准的随机对照试验进行荟萃分析。进行异质性检验及敏感性分析,潜在的发表偏倚采用"漏斗图"分析。结果:中药干预后EGFRIs相关皮疹的缓解程度、中医症状缓解总效应明显优于对照组(P<0.01);实体瘤治疗总有效率、疾病控制率与未予中药干预组相当(P>0.05)。中药干预组患者生活质量明显改善,均未出现治疗相关的不良反应。漏斗图分析及敏感性分析结果提示荟萃分析结果稳定可靠。结论:中药干预可明显缓解EGFRIs相关皮疹,明显缓解中医临床症状,改善患者生活质量,且不影响EGFRIs抗肿瘤疗效。 Objective:To evaluate the effect of traditional Chinese medicines(TCM)on epidermal growth factor receptor inhibitors(EGFRIs)induced rash.Methods:We conducted a systemic search of Pubmed database,Cochrane database,China Science Periodical Database(CSPD)and China National Knowledge Infrastructure(CNKI)using the following words:randomized controlled trails(RCT),TCM,EGFRIs and rash.RCT trails in human were included.Meta-analysis was performed by using Revman software.Heterogeneity analysis and sensitivity analysis were done,publication biases were detected by a funnel plot analysis.Results:TCM intervention significantly improved EGFRIs induced rash and symptoms defined by the TCM(P 0.01).The objective response rate and disease control rate of TCM group was equivalent to controls.In TCM group,patients' quality of life was improved.Conclusion:TCM could significantly relieve EGFRIs induced rash and symptoms,improve patients' quality of life.
出处 《中日友好医院学报》 2016年第1期30-35,共6页 Journal of China-Japan Friendship Hospital
基金 首都临床特色应用研究课题(Z15110700400000) 中日友好医院院级课题(2013-MS-42)
关键词 表皮生长因子受体抑制剂 皮疹 中药 荟萃分析 epidermal growth factor receptor inhibitors rash traditional Chinese medicine meta-analysis
  • 相关文献

参考文献15

  • 1Aggarwal C.Targeted therapy for lung cancer:present and future[J].Ann Palliat Med,2014,3(3):229-235.
  • 2Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361:947-957.
  • 3Chanprapaph K,Vachiramon V,Rattanakaemakorn P.Epidermal growth factor receptor inhibitors:a review of cutaneous adverse events and management[J].Dermatol Res Pract,2014,2014,734249.
  • 4Liu HB,Wu Y,Lv TF,et al.Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer:a systematic review and meta-analysis[J].PLo S One,2013,8(1):e55128.
  • 5Thatcher N,Nicolson M,Groves RW,et al.Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK[J].Oncologist,2009,14(8):840-847.
  • 6Common Terminology Criteria for Adverse Events(CTCAE)v4.0.US Department of Health and Human Services.National Institute of Health[J].National Cancer Institute,2009,http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
  • 7Lacouture ME,Anadkat MJ,Bensadoun RJ,et al.Dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group[J].Supportive Care in Cancer,2010,18(4):509-522.
  • 8王玉艳,王洁.表皮生长因子受体抑制剂相关皮肤不良反应的发生机制与防治[J].癌症进展,2009,7(4):399-406. 被引量:17
  • 9郑筱英.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.243-253.
  • 10Finlay AY,Basra MK,Piguet V,et al.Dermatology life quality index(DLQI):a paradigm shift to patient-centered outcomes[J].J Invest Dermatol,2012,132(10):2464-2465.

二级参考文献61

共引文献150

同被引文献156

引证文献14

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部